BYSI News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

BY

Volume

11.31K

Next Earnings

November 11th

Loading chart

BY

BYSIBeyondSpring Inc. Ordinary Shares

BYSI

Pay with—

Available Balance0.00

BY

Mkt Cap

$23.9M

Volume

11.31K

Next Earnings

November 11th

Chart Financials Earnings News About Insider Filings

BeyondSpring Announces ESMO Asia Presentation on Plinabulin + Docetaxel Improving Survival in Large Phase 3 DUBLIN-3 Asian Subset for EGFR WT NSCLC Compared to Docetaxel, Strengthening the Case for a Global Registration PathBeyondSpring presented Phase 3 DUBLIN-3 trial results showing Plinabulin plus docetaxel improved overall survival in Asian patients with EGFR wild-type non-small cell lung cancer, with reduced neutropenia and promising survival rates.GlobeNewswire Inc. · Dec 12, 2025

SEED Receives FDA Rare Pediatric Disease and Orphan Drug Designations for Lead Oncology Asset RBM39 Degrader and Enters Strategic Transactions with New InvestorsSEED Therapeutics received FDA designations for its lead oncology asset ST-01156, a molecular glue that degrades RBM39. The company also announced strategic transactions with its largest shareholder, BeyondSpring, to diversify its shareholder base.GlobeNewswire Inc. · Jan 28, 2025

BeyondSpring Announces $35.4 Million Sale of a Portion of Equity Interest in SEED Therapeutics to Advance Lead Asset Plinabulin to Anti-Cancer Registrational StudiesBeyondSpring announced the sale of a portion of its equity interest in SEED Therapeutics for $35.4 million. The proceeds will be used to advance the late-stage clinical trials of BeyondSpring's lead asset, Plinabulin, a first-in-class anti-cancer agent.GlobeNewswire Inc. · Jan 28, 2025

BeyondSpring Presents Updated Efficacy Results from a Phase 2 IIT Study of Triple IO Combo of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on Prior Immune Checkpoint Inhibitors at the 39th SITC Annual MeetingBeyondSpring presented updated results from a phase 2 study evaluating a triple combination of pembrolizumab, plinabulin, and docetaxel in metastatic NSCLC patients who progressed on prior immune checkpoint inhibitors. The regimen showed promising efficacy with a disease control rate of 89.3% and median PFS of 8.6 months.GlobeNewswire Inc. · Nov 11, 2024

BeyondSpring Presents Final Data Analysis of DUBLIN-3 Phase 3 Study in 2L/3L EGFR Wild-type NSCLC at ESMO Congress 2024BeyondSpring's plinabulin/docetaxel combination demonstrated significant improvements in overall survival, progression-free survival, and objective response rate compared to docetaxel alone, with an 80% reduction in grade 4 neutropenia and improved patient quality of life.GlobeNewswire Inc. · Sep 16, 2024

BeyondSpring Announces Oral Presentation at the 2024 World Conference on Lung Cancer and Two Poster Presentations During ESMO Congress 2024 Showcasing its Lead Anti-Cancer Asset, PlinabulinBeyondSpring, a clinical-stage biopharmaceutical company, will present data on its lead anti-cancer asset, Plinabulin, at the 2024 World Conference on Lung Cancer and ESMO Congress 2024. The presentations will focus on the final efficacy data of Plinabulin and docetaxel combination in EGFR wild-type 2L/3L non-small cell lung cancer, as well as safety and efficacy results from other studies.GlobeNewswire Inc. · Sep 3, 2024

BeyondSpring To Host Virtual R&D Day to Discuss New Plinabulin Development Strategy for Cancer and Updates for SEED TherapeuticsFLORHAM PARK, N.J., May 03, 2024 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage global biopharmaceutical company focused on developing innovative cancer therapies, today announced it will host a Research and Development (R&D) Day to discuss the current unmet medical needs and the potential of Plinabulin as a novel immunochemotherapeutic in drug combinations and updates for SEED Therapeutics on Wednesday, May 15th, 2024 at 10:00 a.m. ET.GlobeNewswire Inc. · May 3, 2024

BeyondSpring Files 2023 Annual Report on Form 20-FFLORHAM PARK, N.J., April 29, 2024 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage global biopharmaceutical company focused on developing innovative cancer therapies, today announced that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2023 with the U.S. Securities and Exchange Commission (“SEC”) on April 29, 2024. The annual report on Form 20-F, which contains the Company’s audited consolidated financial statements, can be accessed on the SEC’s website at www.sec.gov and on the Company’s website at www.beyondspringpharma.com under “Financials & Filings” in the Investors section.GlobeNewswire Inc. · Apr 29, 2024

BeyondSpring Provides Business Update and Reports Year End 2023 Financial Results- BeyondSpring Dosed First Patient of Two Phase 2 Investigator-Initiated Trials (IIT) in Plinabulin and Keytruda Combination StudiesGlobeNewswire Inc. · Apr 29, 2024

BeyondSpring Announces First Patient Dosed with Pembrolizumab, Plinabulin Plus Etoposide/Platinum in a Phase 2 Investigator-initiated Study of First-Line Extensive-Stage Small-Cell Lung CancerFLORHAM PARK, N.J., March 25, 2024 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage global biopharmaceutical company focused on developing innovative cancer therapies, today announced that the first patient has been dosed in a Phase 2 investigator-initiated trial (IIT) with Pembrolizumab, Plinabulin, BeyondSpring’s lead asset, plus Etoposide/Platinum (EP) for first-line (1L) Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) [NCT05745350].GlobeNewswire Inc. · Mar 25, 2024

to start trading

BY

BYSIBeyondSpring Inc. Ordinary Shares

BYSI

Pay with—

Available Balance0.00

Your PositionYou don't own any BYSI yet.

Related Tickers

Earnings